Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202420 | 0.92 | MCHR1 (0.54) | MCHR1SMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL4269277 | 0.84 | MCHR1 (0.53) | MCHR1SMN1; SMN2RAB9ANPC1GAA | |
| SCHEMBL4258680 | 0.82 | MCHR1 (0.70) | MCHR1 | |
| SCHEMBL3738216 | 0.81 | DOT1L (0.57) | SMN1; SMN2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL31672140 | 0.81 | DOT1L (0.57) | SMN1; SMN2KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6204138 | 0.80 | MCHR1 (0.50) | MCHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6203236 | 0.76 | MCHR1 (0.49) | MCHR1SMN1; SMN2KDM4EMEN1MAPT | |
| SCHEMBL6203321 | 0.76 | HSD17B2 (0.51) | MCHR1SMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL23385627 | 0.75 | MCHR1 (0.47) | MCHR1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6199601 | 0.75 | MCHR1 (0.63) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012061-A1 | A Method of Treating Cancer | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050009815-A1 | 4-Aminoquinoline compounds | DEVITA ROBERT J (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012061-A1 | A Method of Treating Cancer | KIF5B, MKI67, KIF2C | MCHR1 2332/4885SMN1; SMN2 3714/4885KDM4E 885/4885 |
| US-20050009815-A1 | 4-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | MCHR1 1/4885SMN1; SMN2 201/4885KDM4E 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.